Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain

NCT07197645 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT07197645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07197645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Phase 1
Overall status
Recruiting
Start date
October 21, 2025
Completion date
July 5, 2027
Enrollment
33 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases in subjects with advanced cancer, bone pain, metastatic bone tumor